Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.

Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, Hamstra D.

Am J Clin Oncol. 2019 Apr;42(4):382-390. doi: 10.1097/COC.0000000000000521.

PMID:
30724780
2.

Trends in Breastfeeding Disparities in US Infants by WIC Eligibility and Participation.

Zhang Q, Lamichhane R, Wright M, McLaughlin PW, Stacy B.

J Nutr Educ Behav. 2019 Feb;51(2):182-189. doi: 10.1016/j.jneb.2018.10.005. Epub 2018 Dec 1.

PMID:
30514654
3.

WIC Households' Bread and Cold Cereal Purchases: When They Use Benefits Versus Paying Out of Pocket.

Stewart H, McLaughlin PW, Dong D, Frazão E.

Am J Health Promot. 2019 Jan;33(1):79-86. doi: 10.1177/0890117118778243. Epub 2018 May 30.

PMID:
29847997
4.

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2017 Mar 20;2(3):437-454. doi: 10.1016/j.adro.2017.03.003. eCollection 2017 Jul-Sep. Review.

5.

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Expert Panel on Radiation Oncology-Prostate:, Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2016 Oct 20;2(1):62-84. doi: 10.1016/j.adro.2016.10.002. eCollection 2017 Jan-Mar. Review. No abstract available.

6.

External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients.

Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, Spratt DE.

Brachytherapy. 2017 Jul - Aug;16(4):782-789. doi: 10.1016/j.brachy.2017.04.001. Epub 2017 May 9.

PMID:
28499487
7.

Individual and Store Characteristics Associated with Brand Choices in Select Food Category Redemptions among WIC Participants in Virginia.

Zhang Q, Tang C, McLaughlin PW, Diggs L.

Int J Environ Res Public Health. 2017 Mar 31;14(4). pii: E364. doi: 10.3390/ijerph14040364.

8.

Prostate magnetic resonance imaging for brachytherapists: Anatomy and technique.

Venkatesan AM, Stafford RJ, Duran C, Soni PD, Berlin A, McLaughlin PW.

Brachytherapy. 2017 Jul - Aug;16(4):679-687. doi: 10.1016/j.brachy.2016.12.013. Epub 2017 Feb 23.

PMID:
28237429
9.

Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial.

Spratt DE, Lee JY, Dess RT, Narayana V, Evans C, Liss A, Winfield R, Schipper MJ, Lawrence TS, McLaughlin PW.

Eur Urol. 2017 Oct;72(4):617-624. doi: 10.1016/j.eururo.2017.02.007. Epub 2017 Feb 21.

PMID:
28233591
10.

Prostate magnetic resonance imaging for brachytherapists: Diagnosis, imaging pitfalls, and post-therapy assessment.

Venkatesan AM, Stafford RJ, Duran C, Soni PD, Berlin A, McLaughlin PW.

Brachytherapy. 2017 Jul - Aug;16(4):688-697. doi: 10.1016/j.brachy.2016.12.012. Epub 2017 Jan 27. Review.

PMID:
28139419
11.

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.

McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ; Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2017 Feb;40(1):1-10. doi: 10.1097/COC.0000000000000354.

PMID:
28059930
12.

Magnetic resonance imaging-guided functional anatomy approach to prostate brachytherapy.

Soni PD, Berlin A, Venkatesan AM, McLaughlin PW.

Brachytherapy. 2017 Jul - Aug;16(4):698-714. doi: 10.1016/j.brachy.2016.11.009. Epub 2016 Dec 29.

PMID:
28040380
13.

Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.

Moghanaki D, Turkbey B, Vapiwala N, Ehdaie B, Frank SJ, McLaughlin PW, Harisinghani M.

Semin Radiat Oncol. 2017 Jan;27(1):21-33. doi: 10.1016/j.semradonc.2016.08.008. Epub 2016 Aug 31. Review.

14.

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N.

Brachytherapy. 2017 Mar - Apr;16(2):266-276. doi: 10.1016/j.brachy.2016.10.002. Epub 2016 Dec 7.

PMID:
27964905
15.

American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.

Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ.

Brachytherapy. 2017 Jan - Feb;16(1):1-12. doi: 10.1016/j.brachy.2016.09.006. Epub 2016 Oct 19. Review.

PMID:
27771243
16.

Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy.

Lee JY, Spratt DE, Liss AL, McLaughlin PW.

Lancet Oncol. 2016 May;17(5):e198-208. doi: 10.1016/S1470-2045(16)00063-2. Epub 2016 Apr 27. Review.

PMID:
27301047
17.

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.

Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA; PROSTQA Study Consortium.

Radiother Oncol. 2015 Aug;116(2):179-84. doi: 10.1016/j.radonc.2015.07.016. Epub 2015 Aug 11.

PMID:
26276528
18.

Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5.

Liss AL, Abu-Isa EI, Jawad MS, Feng FY, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA.

Brachytherapy. 2015 Jul-Aug;14(4):502-10. doi: 10.1016/j.brachy.2015.02.389. Epub 2015 Apr 22.

PMID:
25911994
19.

ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer.

Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ.

Oncology (Williston Park). 2014 Dec;28(12):1125-30, 1132-6.

20.

ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer.

Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ; American College of Radiology, Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2014 Jun;37(3):278-88. doi: 10.1097/COC.0000000000000049. Review.

PMID:
25180754
21.

Optimal needle design for minimal insertion force and bevel length.

Wang Y, Chen RK, Tai BL, McLaughlin PW, Shih AJ.

Med Eng Phys. 2014 Sep;36(9):1093-100. doi: 10.1016/j.medengphy.2014.05.013. Epub 2014 Jun 21.

PMID:
24957487
22.

Response to Drs Rogers, Hayes, and Demanes.

Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G; Expert Panel on Radiation Oncology–Prostate.

Brachytherapy. 2014 Sep-Oct;13(5):523-5. doi: 10.1016/j.brachy.2014.05.007. Epub 2014 May 28. No abstract available.

PMID:
24880587
23.

Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA.

Am J Clin Oncol. 2016 Apr;39(2):181-8. doi: 10.1097/COC.0000000000000043.

PMID:
24517957
24.

ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer.

Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G.

Brachytherapy. 2014 Jan-Feb;13(1):27-31. doi: 10.1016/j.brachy.2013.11.007. Epub 2013 Dec 22. Review.

PMID:
24368283
25.

Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):721-8. doi: 10.1016/j.ijrobp.2013.03.028. Epub 2013 May 9.

PMID:
23664325
26.

High-dose-rate strictures: a theory of cancer meets anatomic reality.

McLaughlin PW, Narayana V.

Brachytherapy. 2013 May-Jun;12(3):199-201. doi: 10.1016/j.brachy.2013.03.001. Epub 2013 Mar 27. No abstract available.

PMID:
23541480
27.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

28.

Effects of insertion speed and trocar stiffness on the accuracy of needle position for brachytherapy.

McGill CS, Schwartz JA, Moore JZ, McLaughlin PW, Shih AJ.

Med Phys. 2012 Apr;39(4):1811-7. doi: 10.1118/1.3689812.

29.

Novel needle cutting edge geometry for end-cut biopsy.

Moore JZ, McLaughlin PW, Shih AJ.

Med Phys. 2012 Jan;39(1):99-108. doi: 10.1118/1.3665253.

30.

Expansion/de-expansion tool to quantify the accuracy of prostate contours.

Chung E, Stenmark MH, Evans C, Narayana V, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):33-7. doi: 10.1016/j.ijrobp.2011.05.040. Epub 2011 Nov 11.

PMID:
22079729
31.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE.

Ann Oncol. 2012 Jun;23(6):1640-5. doi: 10.1093/annonc/mdr490. Epub 2011 Oct 19.

32.

Precision grid and hand motion for accurate needle insertion in brachytherapy.

McGill CS, Schwartz JA, Moore JZ, McLaughlin PW, Shih AJ.

Med Phys. 2011 Aug;38(8):4749-59.

PMID:
21928648
33.

Greater postimplant swelling in small-volume prostate glands: implications for dosimetry, treatment planning, and operating room technique.

Chung E, Stenmark MH, Evans C, Narayana V, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1944-8. doi: 10.1016/j.ijrobp.2011.03.024. Epub 2011 Jun 2.

PMID:
21640498
34.

Marginal zone lymphomas: factors that affect the final outcome.

Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS.

Cancer. 2010 Sep 15;116(18):4291-8. doi: 10.1002/cncr.25325.

35.

Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy.

McLaughlin PW, Evans C, Feng M, Narayana V.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):369-78. doi: 10.1016/j.ijrobp.2009.02.019. Epub 2009 Jun 8.

PMID:
19515511
36.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42. doi: 10.1016/j.ijrobp.2009.01.029.

PMID:
19409729
37.

Predicting biochemical failure and overall survival through intratherapy PSA changes during definitive external beam radiotherapy.

Soto DE, Andridge RR, Taylor JM, McLaughlin PW, Sandler HM, Pan CC.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1408-15. doi: 10.1016/j.ijrobp.2008.03.013. Epub 2008 May 19.

38.

Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer.

Soto DE, Glaser S, Roberts RH, Schipper MJ, McLaughlin PW, Ray ME, Sandler HM, Pan CC.

Urology. 2008 Feb;71(2):313-7. doi: 10.1016/j.urology.2007.08.037.

PMID:
18308110
39.

Combined permanent implant and external-beam radiation therapy for prostate cancer.

Soto DE, McLaughlin PW.

Semin Radiat Oncol. 2008 Jan;18(1):23-34. Review.

PMID:
18082585
40.

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

Roach M 3rd, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW.

J Urol. 2006 Dec;176(6 Pt 2):S16-20.

PMID:
17084158
41.

Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.

Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Sanda MG.

Urology. 2006 Jul;68(1):166-71.

PMID:
16844457
42.

Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.

Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski J, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief JH, Allen ZA.

Brachytherapy. 2005;4(4):241-51.

PMID:
16344253
43.

Functional anatomy of the prostate: implications for treatment planning.

McLaughlin PW, Troyer S, Berri S, Narayana V, Meirowitz A, Roberson PL, Montie J.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):479-91.

PMID:
16168840
44.

Use and uncertainties of mutual information for computed tomography/ magnetic resonance (CT/MR) registration post permanent implant of the prostate.

Roberson PL, McLaughlin PW, Narayana V, Troyer S, Hixson GV, Kessler ML.

Med Phys. 2005 Feb;32(2):473-82.

45.

Randomized trial of high- and low-source strength (125)I prostate seed implants.

Narayana V, Troyer S, Evans V, Winfield RJ, Roberson PL, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):44-51.

PMID:
15629592
46.

Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI.

McLaughlin PW, Narayana V, Meirovitz A, Troyer S, Roberson PL, Gonda R Jr, Sandler H, Marsh L, Lawrence T, Kessler M.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):20-31. Erratum in: Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1609. Meriowitz, Amichay [corrected to Meirovitz, Amichay].

PMID:
15629590
47.

The use of mutual information in registration of CT and MRI datasets post permanent implant.

McLaughlin PW, Narayana V, Kessler M, McShan D, Troyer S, Marsh L, Hixson G, Roberson PL.

Brachytherapy. 2004;3(2):61-70.

PMID:
15374537
48.

Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.

Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F.

Clin Cancer Res. 2004 Aug 15;10(16):5432-8.

49.

The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.

Pan CC, Lee JS, Chan JL, Sandler HM, Underwood W, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1292-6.

PMID:
14630264
50.

Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy.

Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):384-90.

PMID:
12957249

Supplemental Content

Loading ...
Support Center